4th International Conference on
Pharmaceutical Science & Research

Luca Roncati, MD-PhD, DMLS, is Associate Editor of the European Journal of Gynaecological Oncology (EJGO), Medical Executive at the University Hospital of Modena, and Adjunct Professor at the University of Modena and Reggio Emilia (Italy). Eponym of the Roncati-Manenti triad and describer of T rex lymphoma, he is the author of more than 250 academic publications, he has taken part in the scientific work of various national and international agencies or research groups, he has organized several conferences of national and international relevance, he has attended as a speaker at numerous congresses and seminars, he holds the intellectual property of an Italian and international patent for anticancer therapy, and he has obtained various national and supranational awards.

Gynaecological Pathology; Gynaecological Oncology; Breast Cancer; Lymphoma; Human Papilloma Virus (HPV); HPV Test; PAP Smear.

Professor Salom’s extensive background in both public and private health has endowed her with a wealth of experience collaborating with government entities at all levels. With over 25 years of expertise in health, spanning roles as an academic, pathologist, researcher, and health manager across various locations in Australia, she most recently served as the Director of Pathology at Monash University. During her tenure, Professor Salom played a pivotal role in establishing the single state pathology service, skillfully bringing together over 1800 staff members from 17 hospitals. She was also instrumental in spearheading significant research initiatives, notably the establishment of the Centre of Cancer Biology. Her qualifications include being a Registered Medical Specialist (MB BS, FRCPA), with additional management qualifications (MBA, AFCHSM, FAICD), and research qualifications (MD, BMedSci). Professor Salom holds the distinguished title of Professor at Monash University, from where she graduated. Following her medical studies, Professor Salom pursued her MD at the Department of Pathology and Immunology at Monash University and conducted research at Hammersmith Hospital London. She later specialized in Surgical Pathology and obtained an MBA, leading her to venture into hospital and pathology management. Notably, she served as the Inaugural Executive Director of SA Pathology from 2008 to 2012. During this period, SA Pathology grew into a comprehensive service providing pathology testing, clinical services, and substantial research, operating on a budget exceeding $280M. In addition to her academic and managerial roles, Professor Salom has been actively involved in various health-related projects as the Director of National Health Advisory at KPMG, aimed at enhancing value for clients in both public and private healthcare organizations. Her contributions also extend to governance roles, as a Non-Executive Director at Melbourne Health, where she served on the Board, Clinical Governance and Improvement Committee, Audit Committee, and held a standing position on the Finance and Primary Health committees. Moreover, she acted as a Non-Executive Director at Peninsula Health, holding positions on the Board, Human Ethics Committee, Planning Committee, and Quality and Safety Committee. Furthermore, Professor Salom has demonstrated her capabilities in running a diverse Health business as the Managing Director of Medvet Pty Ltd, where she reported to the Board and took charge of its operations.

Endothelial activation and cytokine expression in human acute cardiac allograft rejection

Dr. Claudia Clavijo is a skilled anesthesiologist with a practice based in Aurora, CO. Her primary focus is on ensuring the safety and well-being of patients who are preparing for surgical procedures. As an anesthesiologist, Dr. Clavijo specializes in various anesthesia techniques, each tailored to the specific needs of the patient. General anesthesia is one of the areas in which Dr. Clavijo is proficient. This technique involves administering medications to induce a state of deep sleep, allowing patients to be completely unconscious and unaware during their surgery. By carefully monitoring vital signs and adjusting the anesthesia as needed, she ensures a smooth and safe surgical experience. In addition to general anesthesia, Dr. Clavijo is experienced in providing sedation. This form of anesthesia helps calm patients and can also induce a state of partial unawareness, reducing anxiety and discomfort during certain medical procedures. Furthermore, Dr. Clavijo is skilled in administering regional anesthesia. This technique involves numbing specific parts of the body, often used in surgeries or medical procedures that do not require full unconsciousness. By targeting only the relevant area, regional anesthesia can effectively control pain while allowing the patient to remain conscious during the procedure. Beyond her crucial role during surgeries, Dr. Clavijo also plays a vital part in post-operative care by managing pain and ensuring patients are comfortable during their recovery period. Her expertise in pain management allows her to provide personalized care and alleviate any discomfort that patients may experience after their operation.

My research interests are mainly focused on the development of analytical methods for the quantification of anesthesia related medication and their metabolites and on the development of low volume sampling techniques as dried blood spots to quantify this compounds.

Heather Sheardown is an esteemed Professor in the Department of Chemical Engineering at the University of Waterloo, with a cross appointment to the Department of Pathology and Molecular Medicine, as well as an adjunct appointment with the School of Optometry. Her contributions to the field have been recognized with a Tier 1 Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery. Throughout her career, Heather Sheardown has been a prolific researcher, having authored over 140 peer-reviewed papers in the area of ophthalmic biomaterials and drug delivery. Her work has significantly advanced the understanding and application of these subjects. Currently, Dr. Sheardown holds the position of Scientific Director at C20/20, an ORF (Ontario Research Fund) funded incubator focused on the commercialization of ophthalmic biotechnologies. This role allows her to facilitate the translation of innovative research into practical applications for ophthalmic treatments. Previously, she served as the Scientific Director of the 20/20 NSERC Ophthalmic Materials Research Network. Under her leadership, this network brought together 12 researchers and more than 10 companies, fostering collaboration for the early-stage development of novel material-based treatments for various ophthalmic conditions. Dr. Sheardown's contributions extend beyond her academic role. She is also the Associate Director of Biomedical Engineering and Advanced Manufacturing (BEAM) at McMaster University, where she collaborates with Fraunhofer IZI and industry partners to incubate and commercialize cell-based therapies, diagnostics, and biomaterials. Her innovative work has resulted in 18 patents or provisional patents, demonstrating her commitment to advancing technology and medical solutions in her field. Currently, she serves as the Chief Scientific Officer of 20/20 Optim Eyes, a spin-out company based at McMaster University. This venture focuses on the development and commercialization of a micelle-based technology that originated from her laboratory. In addition to her remarkable achievements, Dr. Sheardown also leads a dynamic and diverse research group. With over 10 postdoctoral fellows and graduate students, her team contributes to cutting-edge research and innovation in ophthalmic biomaterials and drug delivery.

Drug delivery - Anterior Eye Drug delivery - Posterior Eye Contact Lens IOLs In Vivo Ocular Testing

The individual holds various certifications and degrees in pharmacy, indicating a strong educational background and professional expertise. They are a Board Certified Pharmacotherapy Specialist (BCPS) accredited by the American Pharmacists Association (APhA) in the USA. Additionally, they completed an ASHP-accredited PGY-1 Pharmacy Residency at Lebanese American University & LAU Medical Center-Rizk Hospital in Lebanon in 2019. Their educational achievements include a Doctor of Pharmacy (Pharm.D.) degree with Distinct Honors from Lebanese American University (LAU) in Lebanon in 2019, as well as a Bachelor of Science in Pharmacy (BSc.Pharm) degree with Distinct Honors from the same institution in 2018. Furthermore, the individual earned a certification in the "Antimicrobial Stewardship Certificate Program for Pharmacists" offered by the Society of Infectious Diseases Pharmacists in the USA in 2013. Their academic journey started with a Bachelor of Pharmacy (B.Pharm) degree with Honors from Arab International University (AIU) in Syria in 2011. This impressive combination of degrees and certifications showcases the individual's commitment to advancing their pharmaceutical knowledge and expertise. With their extensive training and professional recognition, they are well-equipped to excel in the field of pharmacy and make valuable contributions to patient care and drug therapy management.

Cardiovascular Pharmacotherapy Critical Care Pharmacotherapy Academic Pharmacy

Samantha Gooden is a highly accomplished individual with an impressive academic and professional background. She has completed graduate studies in Marketing and Entrepreneurship, showcasing her expertise in these fields. Additionally, she pursued post-graduate studies at Harvard University in the USA, specializing in Sustainability Leadership, demonstrating her commitment to environmental and sustainable practices. As a serial entrepreneur, Samantha has a proven track record of establishing and managing successful ventures. She currently serves as the CEO of Scotch Bonnet Ltd. in Trinidad and Tobago, where she leads with strategic vision and innovative ideas. With over 20 years of experience in marketing, communications, telecommunications, and broadcasting, Samantha has honed her skills and knowledge in various industries. Her extensive work spans across more than 15 countries, allowing her to gain a global perspective and a deep understanding of diverse markets. In addition to her business acumen, Samantha possesses a unique background in medical technology, which has likely contributed to her versatility as an author, speaker, lecturer, and trainer. Her expertise in this area provides a solid foundation for her engaging and insightful contributions to the field. Samantha's passion for sharing knowledge and empowering others is evident in her work as a trainer and mentor. Her recent tour in West Africa focused on providing valuable training to marketers, entrepreneurs, and young leaders, inspiring them to achieve their goals and make a positive impact in their respective fields. A well-traveled individual, Samantha enjoys exploring different cultures and embracing new experiences. Her dynamic and diverse background has shaped her into a multi-faceted professional who continues to leave a mark in various industries and inspire others along the way.

Medical technology, Cancer, Biomarkers

Ashraf A Khalil is a distinguished Professor at the City of Scientific Research (SRTA-City) in Egypt. He has a remarkable academic and research background with postdoctoral training at various prestigious departments at Lund University in Sweden. His postdoctoral experiences spanned across the fields of Biotechnology, Developmental Biology, Protein Chemistry, and Neurosurgery. Upon returning to Egypt in 2007, Professor Khalil established his own research team and has been actively supervising numerous biotechnological-oriented studies. His research interests cover a wide range of areas, including disease biomarkers, natural products, bioactive proteins, and proteomics. Throughout his career, Professor Khalil has made significant contributions to the scientific community, publishing over 35 articles in reputable peer-reviewed journals. He is widely recognized and respected in his field, earning membership on the editorial boards of several prestigious peer-reviewed journals. Furthermore, Professor Khalil has been honored with fellowships from the European Organization for Molecular Biology (EMBO) and the American Association for Cancer Research (AACR). These fellowships reflect his outstanding achievements and dedication to advancing molecular biology and cancer research. Beyond his individual accomplishments, Professor Khalil is the visionary founder of the Euro-Mediterranean Association of Life Sciences (EMALS). Under his leadership, EMALS has successfully initiated a series of conferences known as the Euro-Mediterranean Conferences of Natural Products (BioNat). These conferences have served as a platform for the exchange of scientific knowledge and ideas in the field of natural products, and they have been a resounding success. Overall, Professor Ashraf A Khalil's illustrious career, vast research expertise, and visionary leadership have made a lasting impact on the field of life sciences. His contributions to academia, research, and scientific collaboration through EMALS and BioNat have been invaluable in promoting the advancement of biotechnological and natural product studies.

Biotechnology,microbiology,Biomarkers